Top 15 Cancer Stories of 2014

Slideshow

In this slide show we present some of the top cancer stories of 2014, including a newly discovered gene that confers a high-risk of breast cancer and the impressive survival improvement with the addition of docetaxel to ADT in newly diagnosed metastatic prostate cancer.

Recent Videos
A panel of 4 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
A panel of 3 experts on CML
Related Content
Amivantamab plus chemotherapy also improved time to symptomatic progression among patients enrolled on the MARIPOSA-2 trial.

Amivantamab/Chemo Shows Sustained OS in Advanced EGFR+ NSCLC

Darlene Dobkowski, MA
September 14th 2024
Article

Amivantamab plus chemotherapy also improved time to symptomatic progression among patients enrolled on the MARIPOSA-2 trial.

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Jessica Cheng, MD
September 9th 2024
Podcast

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Patients with radioiodine-refractory differentiated thyroid cancer appear to derive benefit from lenvatinib in community and academic settings.

Lenvatinib Improves Efficacy in Real-World Thyroid Cancer Settings

Morgan Bayer
September 14th 2024
Article

Patients with radioiodine-refractory differentiated thyroid cancer appear to derive benefit from lenvatinib in community and academic settings.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

BMS-986012 in combination with nivolumab/chemotherapy showed numerical PFS improvements in those with and without brain metastases at baseline.

Novel Monoclonal Antibody Combo Shows Modest PFS Benefit in Extensive-Stage SCLC

Kristi Rosa
September 13th 2024
Article

BMS-986012 in combination with nivolumab/chemotherapy showed numerical PFS improvements in those with and without brain metastases at baseline.

The phase 3 CAPItello-290 trial of capivasertib plus paclitaxel did not meet its primary end point of improved overall survival in the frontline setting of metastatic triple-negative breast cancer.

Addition of Capivasertib to Paclitaxel Fails to Improve OS in Metastatic TNBC

Kristie L. Kahl
September 13th 2024
Article

The phase 3 CAPItello-290 trial of capivasertib plus paclitaxel did not meet its primary end point of improved overall survival in the frontline setting of metastatic triple-negative breast cancer.